Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Tarsus Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 4 insiders, $5.19M in total
- Insiders trading
- 4
- Net value
- −$5.19M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Tarsus Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pyott David E I | Director | 9,575Indirect | Sep 17, 2026 | 4 |
| Yarno Wendy L | Director | 16,956 | Sep 17, 2026 | 3 |
| Link William J PhD | Director | 94,487 | Sep 17, 2026 | 6 |
| Azamian Bobak R. | President/CEO and Board Chair | 827,991Indirect | Sep 9, 2026 | 8 |
| Lin Elizabeth Yeu | Chief Medical Officer | 1,590Indirect | Sep 9, 2026 | 6 |
| Neervannan Seshadri | Chief Operating Officer | 78,532 | Sep 9, 2026 | 7 |
| Chaudhuri Bhaskar | Director | 11,654 | Jun 29, 2026 | 2 |
| Morrison Scott W | Director | 7,638 | Jun 29, 2026 | 2 |
| Goldberg Andrew D. | Director | 19,654 | Jun 29, 2026 | 2 |
| Goodrich Katherine | Director | 2,233 | Jun 29, 2026 | 4 |
| Farrow Jeffrey S | See Remarks | 56,801 | Jun 17, 2026 | 4 |
| Mottiwala Aziz | Chief Commercial Officer | 61,480 | Mar 19, 2026 | 3 |
| Whitfield Dianne C. | Chief Human Resources Officer | 35,028 | Mar 19, 2026 | 5 |
| Wahl Bryan | General Counsel | 63,959 | Mar 19, 2026 | 3 |
| Crane Rosemary A | Director | 5,350 | Jun 25, 2024 | 0 |
| Trevejo Jose M. | CHIEF MEDICAL OFFICER | 2,251 | Dec 22, 2023 | 0 |
| Greenstein Leonard M. | Chief Financial Officer | 26,785 | Apr 21, 2023 | 0 |
| Holdbrook Mark J. | V.P., Clinical Affairs | 3,191 | Mar 21, 2023 | 0 |
| Ackermann Michael | Director | 1,208,273 | Jul 1, 2022 | 0 |
| Vivo Capital Fund IX, L.P. | 10% Owner | 2,469,001Indirect | May 5, 2022 | 0 |
| Vivo Capital IX, LLC | 10% Owner | 2,469,001Indirect | May 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)4:14 PM ET | Sep 4 | 5 days | Azamian Bobak R.President/CEO and Board Chair | SSale | −10.0K | $90.56 | −$905.6K | −1.2%828.0K after | 2 lots10b5-1 |
| Sep 17, 2026 (view filing)4:22 PM ET | Sep 15 | 2 days | Link William J PhDDirector | SSale | −12.5K | $78.38 | −$979.7K | −11.7%94.5K after | 3 lots10b5-1 |